Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + streptozocin + hydrocortisone + vincristine
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal, Oral
01
Overview
**Methotrexate + streptozocin + hydrocortisone + vincristine** is a four-drug chemotherapy combination consisting of methotrexate (an antifolate that inhibits dihydrofolate reductase to block DNA synthesis), streptozocin (a nitrosourea alkylating agent that methylates DNA and inhibits purine synthesis), hydrocortisone (a glucocorticoid that induces apoptosis in lymphoid cells and reduces inflammation), and vincristine (a vinca alkaloid that binds tubulin to disrupt microtubule formation and mitosis). This regimen is used in oncology for cancers responsive to alkylating agents and antimetabolites, such as neuroendocrine tumors or lymphomas, leveraging synergistic cytotoxic effects through diverse mechanisms targeting DNA, cell division, and steroid-sensitive pathways. No specific developer or branded product exists for this exact combination; it appears as a custom or investigational multi-agent protocol.[7][10]
- Other names
- MTX + streptozocin + hydrocortisone + vincristine
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)DNA
Beyond the preview
Go deeper on methotrexate + streptozocin + hydrocortisone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + streptozocin + hydrocortisone + vincristine.